@article{ffa6b0a24cc64133b6219149d4515e9d,
title = "Six versus 12 months{\textquoteright} adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT",
author = "{PERSEPHONE Steering Committee and Trial Investigators} and Helena Earl and Louise Hiller and Anne-Laure Vallier and Shrushma Loi and Karen McAdam and Luke Hughes-Davies and Daniel Rea and Donna Howe and Kerry Raynes and {B Higgins}, Helen and Maggie Wilcox and Chris Plummer and Betania Mahler-Araujo and Elena Provenzano and Anita Chhabra and Sophie Gasson and Claire Balmer and Jean Abraham and Carlos Caldas and Hall, {Peter S} and Bethany Shinkins and Christopher McCabe and Claire Hulme and David Miles and {M. Wardley}, Andrew and Cameron, {David A} and {A Dunn}, Janet",
year = "2020",
month = sep,
day = "2",
doi = "10.3310/hta24400",
language = "English",
journal = "Health Technology Assessment",
issn = "1366-5278",
publisher = "NIHR Health Technology Assessment Programme",
}